For instance, the review showed that GLP-1 drugs may have promising outcomes for people with dementia or other neurological disorders
Patients taking the Wegovy injection (2.4 mg weekly) lost an average of 14.9% over 68 weeks
This goes directly against the mantra of informed consent, Mohit Sodhi, the studys author and a UBC medical student researching the adverse events of common medications, said in a statement.
Clinical trials have shown that semaglutide and liraglutide are generally well tolerated, with gastrointestinal disorders being the most commonly reported AEs, including nausea, diarrhea, vomiting, and constipation, leading to dose reduction or temporary treatment interruption in 12.5% of study participants [40,41,42]
Semaglutide: Semaglutide is a revolutionary GLP-1 receptor agonist that has garnered significant attention for its effectiveness in managing obesity and type 2 diabetes
J Pharm Pharm Sci